An observational study in Cardio Vascular Disease, Acute Coronary Syndromes (ACS) and Type 2 Diabetes, sponsored by Weill Cornell Medical College in Qatar. Not yet recruiting at 1 site in Qatar. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Weill Cornell Medical College in Qatar · Observational
Cardiovascular disease is the leading cause of death worldwide, and individuals with diabetes or other cardiometabolic conditions are at increased risk of adverse cardiovascular outcomes. Although advances in prevention and treatment have reduced cardiovascular events globally, cardiometabolic disease continues to represent a significant health burden, particularly in regions with high diabetes prevalence. In Qatar and other Gulf Cooperation Council countries, the prevalence of diabetes and obesity is increasing, contributing to a high proportion of participants presenting with acute coronary syndrome who have type 2 diabetes or prediabetes. This observational study will use electronic medical record data from patients hospitalized at the Heart Hospital with acute coronary syndrome and a concomitant diagnosis of diabetes or prediabetes. The study will assess trends in cardiovascular risk factors and cardiovascular events, including readmission and mortality. An artificial intelligence component will be used to develop and validate machine learning based risk prediction models to forecast adverse cardiovascular outcomes in participants with cardiometabolic disease. These models will integrate clinical, biochemical, imaging, and other non-invasive data routinely collected during participants care to identify predictors of cardiovascular events.
This study combines retrospective and prospective designs.
Retrospective:
We use past electronic medical records to identify participants and collect baseline information from their initial visit (using their code or health card number).
Prospective:
From that starting point, we follow the same participants forward in time, updating data every two years and recording new outcomes (mortality, cardiovascular events, rehospitalizations, treatment-related outcomes) at planned checkpoints (approximately 6 months, 1 year, and 2 years).
New eligible participants identified in later data extractions are added and followed in the same manner. Because we only observe and record participants existing records and outcomes without assigning interventions, the study is observational.
1,488 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Browse Acute Coronary Syndrome studies →Weill Cornell Medical College in Qatar is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants admitted at Hamad Medical Corporation for Acute Coronary Syndrome (ACS) or Acute Heart Failure (AHF).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Incidence of 3-point Major Adverse Cardiovascular Events (MACE) in Acute Coronary Syndrome Patients
Composite endpoint defined as the occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Events will be identified using electronic medical records, hospital admission data, and follow-up assessments during the study period. These outcomes will serve as endpoints for the development and validation of predictive machine learning models.
Time frame: 5 years
Incidences of 2-point Major Adverse Cardiovascular Events (MACE) in Heart Failure Patients
Composite endpoint defined as cardiovascular death or hospitalization for heart failure. Events will be ascertained through hospital records, clinical documentation, and follow-up data collection. These outcomes will be used as endpoints for predictive model development and validation.
Time frame: 5 years
Major Adverse Cardiovascular Events
MACE - Major Adverse Cardiovascular Events
Time frame: 5 years
Unstable angina requiring hospitalization
Time frame: 5 years
Arrhythmic events
Time frame: 5 years
Coronary revascularization
Time frame: 5 years
Post-Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG) complications (stent/graft thrombosis or repeat revascularization)
Time frame: 5 years
Development or progression of valvular heart disease (aortic or mitral stenosis/regurgitation)
Time frame: 5 years
New-onset diabetes mellitus
Time frame: 5 years
Change in glycated Hemoglobin A1c (HbA1c)
Time frame: 5 years
Newly diagnosed medical or surgical conditions not present at baseline
Time frame: 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Cornell Medical College in Qatar